Recommended Topic Related To:

Vira-A

"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...

Vira-A

Discontinued Warning IconPlease Note: This Brand Name drug is no longer available in the US.
(Generic versions may still be available.)

Overdosage
Contraindications

OVERDOSE

Acute massive overdosage by oral ingestion of the ophthalmic ointment has not occurred. However, the rapid deamination to arabinosylhypoxanthine should preclude any difficulty. The oral LD50 for vidarabine is greater than 5020 mg/kg in mice and rats. No untoward effects should result from ingestion of the entire contents of the tube.

Overdosage by ocular instillation is unlikely because any excess should be quickly expelled from the conjunctival sac.

CONTRAINDICATIONS

VIRA-A (vidarabine) Ophthalmic Ointment, 3%, is contraindicated in patients who develop hypersensitivity reactions to it.

Last reviewed on RxList: 4/8/2009
This monograph has been modified to include the generic and brand name in many instances.

Overdosage
Contraindications
A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.